Company Overview
Snapshot
Founded in January 2020 by Shlomit Steinberg-Koch and Benny Getz, Predicta Med operates with 11–50 employees. The company has raised $5.5 million across two funding rounds from CerraCap Ventures and Prof. Moshe Shoham. In January 2024, Predicta Med secured a grant from the Israel Innovation Authority.
Business overview
Predicta Med develops an AI-powered platform for the early detection and intervention selection of autoimmune diseases. Its core technology leverages deep learning to aggregate, enrich, and analyze EMR and claims data, identifying patients at risk and providing actionable insights for healthcare providers. The platform aims to shorten the diagnostic process for autoimmune diseases, enhancing provider efficiency, improving treatment effectiveness, and optimizing patient care within the digital healthcare sector, specifically targeting medical decision support for healthcare providers.
Strategic signal
In June 2024, Predicta Med's CEO, Shlomit Steinberg-Koch, participated in a Growth+ project meeting organized by Calcalist and Poalim Tech, sharing insights on leadership and crisis management. This engagement highlights the company's active role in the startup ecosystem and its leadership's focus on strategic resilience, signaling a mature approach to navigating operational challenges and fostering growth in the health tech industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Predicta Med's primary focus?
- Predicta Med focuses on the early detection and intervention selection of autoimmune diseases using an AI-powered platform.
- When was Predicta Med founded and by whom?
- Predicta Med was founded in January 2020 by Shlomit Steinberg-Koch and Benny Getz.
- Has Predicta Med received any grants recently?
- In January 2024, Predicta Med secured a grant from the Israel Innovation Authority.
- What was a significant partnership for Predicta Med in 2023?
- In July 2023, Predicta Med joined the Cedars-Sinai Accelerator, receiving mentorship and an investment from Cedars-Sinai as part of its ninth accelerator class.
- Which investor provided funding to Predicta Med in February 2023?
- In February 2023, Predicta Med received an investment from CerraCap Ventures to accelerate growth and expand operations.